Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents

1 februari 2019 uppdaterad av: Mercè Jodar-Vicente, Corporacion Parc Tauli

Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents. Relationship With Clinical and Sociodemographic Variables

Study about the improvement of cognitive, psychopathological and functional abilities in Hepatitis C Virus (HCV) infected patients after eradication of the virus with direct antiviral agents.

Studieöversikt

Status

Avslutad

Betingelser

Detaljerad beskrivning

The aim of this study is to investigate the effect that the eradication of the HCV has on cognition, quality of life and psychopathology. At the same time, investigators intend to study the association between cognitive changes and some clinical variables.

The sample consists of 80 subjects (40 HCV patients and 40 HCV patients coinfected with the Human Immunodeficiency Virus, HIV). Exclusion criteria: Cirrhosis, presence of minimal hepatic encephalopathy or active drug consumption.

A neuropsychological assessment is made before the treatment with direct antiviral agents to evaluate memory, executive functions, processing speed, anxiety, depression and quality of life. Additionally, the following clinical variables are collected: Viral charge, immunosuppression (measured with T Cells CD4 (CD4), CD4 nadir and T Cells CD8 (CD8)) and fibrosis level, HCV genotype and plasma biomarkers: Brain-Derived Neurotrophic Factor (BDNF), Interleukine 6 (IL6), Tumor Necrosis Factor (TNF-a),Glial fibrillary acidic protein (GFAP), Soluble CD14 (SCD14), Neuro-specific enolase (NSE).

The second neuropsychological assessment and clinical data collection is carried out after treatment, concretely 6 months after HCV is undetectable in plasma.

Studietyp

Observationell

Inskrivning (Faktisk)

80

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

N/A

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

HCV patients who are candidates to direct antiviral treatment

Beskrivning

Inclusion Criteria:

  • Patients over 18 years old with indication to receive antiviral treatment
  • Diagnosis of chronic infection by hepatitis C virus in the fibrous phase F3 or F4 that have not presented any clinical decompensation of their liver disease, with or without HIV co-infection

Exclusion Criteria:

  • Active alcohol consumption> 40g daily or history of chronic alcoholism
  • Active consumption of other toxics (heroin, cocaine, cannabis)
  • Patients with minimum hepatic encephalopathy
  • Background of cerebral neurological disease, chronic renal insufficiency and / or psychiatric illnesses assessed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, which can affect cognitive functions.
  • Active use of psychotropics or benzodiazepines

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Memory tests
Tidsram: baseline, change at 6 months after treatment
Rey Auditory Verbal Learning Test (RVLT, Spreen & Strauss 1998) assesses verbal learning, recall and recognition memory; Wechsler Adults Intelligence Scale III backward digits subtest (WAIS, Wechsler 1997) assesses working memory. All direct scores have been transformed into T-scores (mean=50; SD=10), which allows to obtain a single memory component.
baseline, change at 6 months after treatment
Attention tests
Tidsram: baseline, change at 6 months after treatment
Continous Performance Test (CPT, Conners 2000) assesses sustained attention, inattentiveness and impulsivity; WAIS forward digits subtest (WAIS III, Wechsler 1997) assesses attention. All direct scores have been transformed into T-scores (mean=50; SD=10), which allows to obtain a single attention component.
baseline, change at 6 months after treatment
Executive function tests
Tidsram: baseline, change at 6 months after treatment
Stroop Test (Stroop, 1935) assesses flexibility and inhibition of automatic responses; Trail Making Test (TMTA-B Reitan, 1993) assesses visual tracking and flexibility, phonetic and semantic fluency tests (Lezak, 1995) assess verbal fluency; Tower of London (Culbertson & Zillmer, 2005) assesses visual reasoning and planification. All direct scores have been transformed into T-scores (mean=50; SD=10), which allows to obtain a single executive function component.
baseline, change at 6 months after treatment
Speed processing test
Tidsram: baseline, change at 6 months after treatment
Digit symbol test (WAIS III, Wechsler 1997) assesses visuomotor speed. The direct scores have been transformed into T-scores (mean=50; SD=10).
baseline, change at 6 months after treatment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Hospital Anxiety and Depression Scale (HADS)
Tidsram: baseline, change at 6 months after treatment

It is a self-registering scale of 14 items: 7 items evaluating anxiety and 7 items evaluating depression (Zigmond & Snaith, 1983).

Scoring range: 0-21 for each subscale. Scores >10 in each subscale imply a significant anxious/depressive symptomatology.
baseline, change at 6 months after treatment
36-Item Short Form Health Survey (SF-36 )
Tidsram: baseline, change at 6 months after treatment
It is a self-registered scale for the assessment of quality of life ( Alonso y cols. , 1995). It consists on 8 dimensions: Physical functioning, limitations for physical issues, corporal pain, social functioning, mental health, limitations for emotional issues, vitality and general perception of the own health. For each dimension, the scoring range goes from 0 to 100, where higher values represent better outcome (better quality of life/less limitations/better functioning).
baseline, change at 6 months after treatment
Fibroscan
Tidsram: Baseline, change at 6 months after treatment
Degree of fibrosis: Speed of propagation of elastic waves measured with fibroscan.
Baseline, change at 6 months after treatment
HCV RNA
Tidsram: Baseline, change at 3 months after treatment, change at 6 months after treatment.
Viral load quantity measured by plasma HCV RNA is collected in HIV co-infected patients
Baseline, change at 3 months after treatment, change at 6 months after treatment.
Immunosuppression state
Tidsram: Baseline
The next cells were analyzed in blood, in HIV co-infected patients : CD4, %CD4, nadir CD4, CD8, % CD8, CD4/CD8 ratio.
Baseline

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Blood Biomarkers measures
Tidsram: 1 day pretreatment and change at 6 months post treatment
The next blood biomarkers were collected: Brain-derived neurotrophic factor (BDNF); Interleukine 6 (Il-6); Tumor Necrosis Factor (TNF-a ); Glial fibrillary acidic protein (GFAP); Soluble SCD 14 (sCD14) ; Neuro-specific enolase (NSE).
1 day pretreatment and change at 6 months post treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Corporacion Parc Tauli

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

28 juli 2016

Primärt slutförande (Faktisk)

6 september 2017

Avslutad studie (Faktisk)

15 december 2018

Studieregistreringsdatum

Först inskickad

28 mars 2018

Först inskickad som uppfyllde QC-kriterierna

16 april 2018

Första postat (Faktisk)

25 april 2018

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 februari 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 februari 2019

Senast verifierad

1 februari 2019

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • CIR2015/042

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på HCV saminfektion

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Benin

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

Prenumerera